株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の腫瘍市場予測 2023年:免疫チェックポイント阻害薬の普及率上昇・利用拡大による力強い成長

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

発行 GlobalData 商品コード 530489
出版日 ページ情報 英文 420 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
世界の腫瘍市場予測 2023年:免疫チェックポイント阻害薬の普及率上昇・利用拡大による力強い成長 Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors
出版日: 2017年06月13日 ページ情報: 英文 420 Pages
概要

世界の腫瘍市場における収益は、2016年の1,186億米ドルから2023年の2,410億米ドルへ、10.66%のCAGR (年間複合成長率) で拡大すると予測されています。

当レポートでは、世界の腫瘍市場について調査し、上市製品情勢の概要、主要パイプラインの分析、世界および主要国市場における収益予測、企業情勢の分析、および共同開発・ライセンシング契約動向の分析などを提供しています。 第1章 目次

第2章 イントロダクション

第3章 主な上市製品

第4章 パイプライン情勢の評価

  • 概要
  • パイプライン開発情勢
  • パイプラインにおける分子標的
  • 臨床試験
    • 失敗率:開発段階、適応症、分子タイプ、および分子標的別
    • 臨床試験規模・期間:開発段階、適応症、分子タイプ、および分子標的別
    • 総臨床プログラム規模
  • 主なパイプライン製品の評価:開発段階、適応症、分子タイプ、および分子標的別
    • Durvalumab - AstraZeneca
    • Durvalumab and Tremelimumab - AstraZeneca
    • Abemaciclib - Eli Lilly
    • Rova-T (rovalpituzumab tesirine) - AbbVie
    • Neratinib - Puma Biotechnology
    • Acalabrutinib - AstraZeneca
    • KTE-C19(Axicabtagene Ciloleucel) - Kite Pharma
    • Tisagenlecleucel-T - Novartis
    • 結論

第5章 マルチシナリオの市場予測

  • 全体的な市場規模
  • ジェネリック医薬品の普及
  • 収益予測:分子標的別
    • プログラム細胞死タンパク質1 (PD-1) /プログラム細胞死リガンド-1(PD-L1)
    • 腫瘍壊死因子
    • チロシン - プロテインキナーゼBTK
    • サイクリン依存性キナーゼ
    • アンドロゲン受容体
    • 血管内皮増殖因子

第6章 企業分析・ポジショニング

  • 収益・市場シェア分析:企業別
    • Roche
    • Celgene
    • Novartis
    • Bristol-Myers Squibb
    • Pfizer
    • AstraZeneca
  • 企業情勢
  • 上市・パイプライン製品のポートフォリオ分析

第7章 戦略的な検討事項

  • ライセンシング契約
  • 共同開発契約

第8章 付録

目次
Product Code: GBIHC446MR

Executive Summary:

Oncology comprises a large and diverse group of indications, encompassing virtually all sites and tissues in the human body. The diseases are characterized by abnormal cell proliferation, which is followed by local tissue invasion and, at an advanced stage of the disease, the migration of the cancer cells to other parts of the body. Cancer is a genetically driven disease, with iterative mutations providing selective advantages to the cells in the context of the specific tissue site, followed by clonal expansion.

Cancer is anticipated to become increasingly prevalent due to aging populations and rising levels of obesity in the developed world. Furthermore, the development and approval of more targeted oncology treatments is anticipated to decrease toxicity and increase chemotherapy usage in elderly patients. Targeted treatment administration will increase the overall survival of poor-performance-status patients (having impaired functional status) and enable more rounds of chemotherapy to be administered.

In 2012, there were 32.6 Million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Key market players (as determined by the total oncology revenue), namely Roche, Celgene, Bristol Myers Squibbs and Novartis, are forecast to maintain their strong market shares throughout the forecast period. Nevertheless, despite the approaching patent expiries of Avastin, Kadcyla, Perjeta and Tarceva, Roche is expected to maintain the highest market share of any company.

The report "Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors" provides an introduction to oncology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided.

In particular, this report provides the following analysis -

  • Provides an overview of the oncology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the oncology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: breast, colorectal, lung and prostate cancer. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
  • Assesses the company landscape in oncology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenue.
  • Analyzes trends in co-development and licensing deals relating to oncology products. Some of the most prominent deals are discussed in detail.

Scope:

  • Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
  • What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?
  • How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
  • What proportion of the key players' revenues will be attributable to oncology products?

Reasons to buy:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
  • Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
  • Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
  • Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Symptoms
  • 2.3. Diagnosis
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Etiology
    • 2.4.2. Pathophysiology
  • 2.5. Co-morbidities and Complications
  • 2.6. Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
    • 2.6.1. Breast Cancer
    • 2.6.2. Colorectal Cancer
    • 2.6.3. Lung Cancer
    • 2.6.4. Prostate Cancer
    • 2.6.5. Hematological Cancers
  • 2.7. Prognosis
    • 2.7.1. Breast Cancer
    • 2.7.2. Colorectal Cancer
    • 2.7.3. Non-Small-Cell Lung Cancer
    • 2.7.4. Prostate Cancer
  • 2.8. Treatment
    • 2.8.1. Surgery and Radiation Therapy
    • 2.8.2. Chemotherapy
    • 2.8.3. Hormonal Therapies
    • 2.8.4. Targeted Therapies

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. MabThera/Rituxan (rituximab)
  • 3.3. Avastin (bevacizumab)
  • 3.4. Herceptin (trastuzumab)
  • 3.5. Revlimid (lenalidomide)
  • 3.6. Opdivo (nivolumab)
  • 3.7. Xtandi (enzalutamide)
  • 3.8. Gleevec/Glivec (imatinib mesylate)
  • 3.9. Alimta (pemetrexed)
  • 3.10. Zytiga (abiraterone acetate)
  • 3.11. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Conclusion
  • 4.5. Assessment of Key Pipeline Products
    • 4.5.1. Durvalumab - AstraZeneca
    • 4.5.2. Durvalumab and Tremelimumab - AstraZeneca
    • 4.5.3. Abemaciclib - Eli Lilly
    • 4.5.4. Rova-T (rovalpituzumab tesirine) - AbbVie
    • 4.5.5. Neratinib - Puma Biotechnology
    • 4.5.6. Acalabrutinib - AstraZeneca
    • 4.5.7. KTE-C19(Axicabtagene Ciloleucel) - Kite Pharma
    • 4.5.8. Tisagenlecleucel-T - Novartis
    • 4.5.9. Conclusion

5. Multi-scenario Market Forecast to 2023

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Programmed Cell Death Protein 1/Programmed Cell Death 1 Ligand 1
    • 5.3.2. Tumor Necrosis Factor
    • 5.3.3. Tyrosine-Protein Kinase BTK
    • 5.3.4. Cyclin-Dependent Kinases
    • 5.3.5. Androgen Receptor
    • 5.3.6. Vascular Endothelial Growth Factor

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset the Patent Expiries of Avastin and Herceptin?
    • 6.1.2. Celgene - How Will Multiple Patent Expiries Affect Oncology-Related Revenues?
    • 6.1.3. Novartis - How Will Mekinist plus Tafinlar and Tasigna Perform over the Forecast Period?
    • 6.1.4. Bristol-Myers Squibb - How Successful Will Recent Approvals Opdivo and Empliciti Become?
    • 6.1.5. Pfizer - What Do Sutent and Inlyta Patent Expiries Mean for Pfizer?
    • 6.1.6. AstraZeneca - How Will its Immune Checkpoint Inhibitors Durvalumab and Tremelimumab Perform?
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued $1 billion and Above

8. Appendix

  • 8.1. References
  • 8.2. Abbreviations
  • 8.3. Methodology
    • 8.3.1. Secondary Research
    • 8.3.2. Market Size and Revenue Forecasts
    • 8.3.3. Pipeline Analysis
    • 8.3.4. Competitive Landscape
  • 8.4. Contact Us
  • 8.5. Disclaimer

List of Tables

  • Table 1: Oncology, Global, Symptoms of Key Indication Cancers, 2017
  • Table 2: Complications Associated with Breast, Colorectal, Lung, Prostate and Hematological Cancers
  • Table 3: Oncology, Global, Epidemiology of Key Indication Cancers, 2017
  • Table 4: Oncology Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
  • Table 5: Oncology Market, US, Colorectal Cancer Stage and Survival Rates (%), 2017
  • Table 6: Oncology Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
  • Table 7: Oncology, US, Prostate Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
  • Table 8: Optimal and Actual Chemotherapy Usage Rates, 2010
  • Table 9: Oncology Therapeutics Market, Global, Approved Indications for Rituxan, 2017
  • Table 10: Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2017
  • Table 11: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2017
  • Table 12: Oncology Therapeutics Market, Global, Approved Indications for Revlimid, 2017
  • Table 13: Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2017
  • Table 14: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2017
  • Table 15: Oncology Therapeutics Market, Global, Approved Indications for Gleevec, 2017
  • Table 16: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2017
  • Table 17: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2017
  • Table 18: Oncology, Global, Market Size ($bn), 2016-2023 (Part 1)
  • Table 19: Oncology, Global, Market Size ($bn), 2016-2023 (Part 2)
  • Table 20: Oncology, Global, Usage of Generics Across Key Indications, 2017
  • Table 21: Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023
  • Table 22: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Table 23: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Table 24: Oncology, Global, All Pipeline Products, 2017
  • Table 25: Abbreviations

List of Figures

  • Figure 1: Oncology, Major Markets, Treatment Usage Patterns for Breast Cancer, Patients (millions), 2016-2022
  • Figure 2: Oncology, Major Markets, Treatment Usage Patterns for Colorectal Cancer, Patients ('000), 2016-2023
  • Figure 3: Oncology, Major Markets, Treatment Usage Patterns for Lung Cancer, Patients ('000), 2016-2023
  • Figure 4: Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (millions), 2016-2021
  • Figure 5: Oncology, Major Markets, Treatment Usage Patterns for Hematological Cancer, Patients ('000), 2016-2023
  • Figure 6: Oncology, Global, Key Marketed Products and Approved Indications, 2017
  • Figure 7: Oncology, Global, Annual Revenue for Rituxan ($bn), 2006-2023
  • Figure 8: Oncology, Global, Annual Revenues for Avastin ($bn), 2006-2023
  • Figure 9: Oncology, Global, Annual Revenues for Herceptin ($bn), 2006-2023
  • Figure 10: Oncology, Global, Annual Revenue for Revlimid ($bn), 2006-2023
  • Figure 11: Oncology, Global, Annual Revenues for Opdivo ($bn), 2014-2023
  • Figure 12: Oncology, Global, Annual Revenues for Xtandi ($bn), 2012-2023
  • Figure 13: Oncology, Global, Annual Revenues for Gleevec ($bn), 2006-2023
  • Figure 14: Oncology, Global, Annual Revenues for Alimta ($bn), 2006-2023
  • Figure 15: Oncology, Global, Annual Revenues for Zytiga ($bn), 2011-2023
  • Figure 16: Oncology, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
  • Figure 17: Oncology, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2017
  • Figure 18: Oncology, Global, Pipeline for Key Oncology Indications by Stage of Development, 2017
  • Figure 19: Oncology, Global, Pipeline for Key Oncology Indications by Molecule Type, 2017
  • Figure 20: Oncology, Global, Pipeline for Oncology by Molecular Target, 2017
  • Figure 21: Oncology, Pipeline by Mechanism of Action and Stage of Development, 2017
  • Figure 22: Oncology, Global, Pipeline for Key Oncology Indications by Molecular Target, 2017
  • Figure 23: Oncology, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
  • Figure 24: Oncology, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
  • Figure 25: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
  • Figure 26: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
  • Figure 27: Oncology, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
  • Figure 28: Oncology, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
  • Figure 29: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
  • Figure 30: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
  • Figure 31: Oncology, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
  • Figure 32: Oncology, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 33: Oncology, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 34: Oncology, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 35: Oncology, Global, Clinical Program Size by Stage of Development (participants), 2006-2017
  • Figure 36: Oncology, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 37: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 38: Oncology, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 39: Oncology, Global, Revenue Forecast for Durvalumab ($bn), 2017-2023
  • Figure 40: Oncology, Global, Revenue Forecast for Durvalumab + Tremelimumab ($bn), 2017-2023
  • Figure 41: Oncology, Global, Revenue Forecast for Abemaciclib ($bn), 2018-2023
  • Figure 42: Oncology, Global, Revenue Forecast for Rova-T ($bn), 2018-2023
  • Figure 43: Oncology, Global, Revenue Forecast for Neratinib ($bn), 2016-2023
  • Figure 44: Oncology, Global, Revenue Forecast for Acalabrutinib ($bn), 2018-2023
  • Figure 45: Oncology, Global, Revenue Forecast for Axicabtagene Ciloleucel ($bn), 2017-2023
  • Figure 46: Oncology, Global, Revenue Forecast for Tisagenlecleucel-T ($bn), 2017-2023
  • Figure 47: Oncology, Global, Market Size ($bn), 2016-2023
  • Figure 48: Oncology, Global, Generic Penetration for Annual Revenue Forecasts ($bn), 2016-2023
  • Figure 49: Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1/ Programmed Cell Death 1 Ligand 1 ($bn), 2016-2023
  • Figure 50: Oncology, Global, Annual Revenue Forecast for Tumor Necrosis Factor ($bn), 2016-2023
  • Figure 51: Oncology, Global, Annual Revenue Forecast for Tyrosine-Protein Kinase BTK ($bn), 2016-2023
  • Figure 52: Oncology, Global, Annual Revenue Forecast for Cyclin-Dependent Kinases ($bn), 2016-2023
  • Figure 53: Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2016-2023
  • Figure 54: Oncology, Global, Annual Revenue Forecast for Vascular Endothelial Growth Factor ($bn), 2016-2023
  • Figure 55: Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2016-2023
  • Figure 56: Oncology, Global, Company Analysis Matrix, 2017
  • Figure 57: Oncology, Global, Forecast Market Share by Company (%), 2016-2023
  • Figure 58: Oncology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
  • Figure 59: Oncology, Global, Revenues by Product Type, 2016-2023
  • Figure 60: Oncology, Global, Roche Oncology Annual Revenue Forecast ($bn), 2016-2023
  • Figure 61: Oncology, Global, Celgene Annual Revenue Forecast ($bn), 2016-2023
  • Figure 62: Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2016-2023
  • Figure 63: Oncology, Global, Bristol-Myers Annual Revenue Forecast ($bn), 2016-2023
  • Figure 64: Oncology, Global, Pfizer Annual Revenue Forecast ($bn), 2016-2023
  • Figure 65: Oncology, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023
  • Figure 66: Oncology, Global, Companies by Type, 2016-2023
  • Figure 67: Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Oncology Specialization, 2016-2023
  • Figure 68: Oncology, Global, Proportion of Total Company Revenue Attributed to Cancer, 2016-2023
  • Figure 69: Oncology, Global, Licensing Deals, 2006-2017
  • Figure 70: Oncology, Global, Licensing Deals by Indication and Value, 2006-2017
  • Figure 71: Oncology, Global, Licensing Deals by Volume and Value, 2006-2017
  • Figure 72: Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2017
  • Figure 73: Oncology, Global, Co-development Deals, 2006-2017
  • Figure 74: Oncology, Global, Co-development Deals by Indication and Value, 2006-2017
  • Figure 75: Oncology, Global, Co-development Deals by Volume and Value, 2006-2017
  • Figure 76: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
Back to Top